Imatinib Improved the Overall Survival of Chronic Myeloid Leukemia Patients in Low- And Middle-Income Countries: A Therapeutic Goal Has Been Reached

EClinicalMedicine - United Kingdom
doi 10.1016/j.eclinm.2020.100277
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Elsevier BV

Related search

Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients

2012English

The Development of Imatinib as a Therapeutic Agent for Chronic Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2005English

Advancing STI Care in Low/Middle-Income Countries: Has STI Syndromic Management Reached Its Use-By Date?

Sexually Transmitted Infections
DermatologyInfectious Diseases
2016English

Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients With Chronic Myeloid Leukemia

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
2015English

Improved Drug Access in Low and Middle-Income Countries

The Lancet Oncology
Oncology
2016English

Cost Effectiveness of Therapeutic Drug Monitoring for Imatinib Administration in Chronic Myeloid Leukemia

PLoS ONE
Multidisciplinary
2019English

Imatinib and Plasmacytoid Dendritic Cell Function in Patients With Chronic Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2004English

Gene Expression Signature of Primary Imatinib-Resistant Chronic Myeloid Leukemia Patients

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2006English

Dasatinib in the Treatment of Imatinib Refractory Chronic Myeloid Leukemia

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy